A s cancer cells become resistant to drugs that target cancer-specific signalling pathways, an intriguing phenomenon called drug addiction sometimes develops 1 . This occurs when cells that are resistant to drug treatment become dependent on the drug. On page 270, Kong et al. 2 provide insights into the mechanisms underlying drug addiction in cancer. Their findings have major implications for the use of targeted tumour therapies.
The authors studied cultured cell samples of a type of human skin cancer called melanoma. They treated the cells with the drug dabrafenib, which is used to target the BRAF protein in cancers that have a cancer-causing mutation in the BRAF gene. Alternatively, the authors treated the cells with both dabrafenib and the drug trametinib, which targets an enzyme in the BRAF pathway called MEK. They identified drug-addicted cells, which died if they did not receive drug treatment.
To find the mechanism responsible for drug addiction in this context, Kong and colleagues used a genetic-engineering technique to delete genes in the cells. They withdrew dabrafenib from the engineered cells, then analysed the surviving cells for genes whose deletion prevented the cell death or growth arrest that usually occurs in drug-addicted cells when the drug is withdrawn. These experiments enabled the authors to identify two genes that they verified were involved in the drug-addiction process. The genes encode the proteins ERK2 and JUNB, which have roles in the BRAF-mediated signalling pathway. Then, using a panel of drug-resistant cell lines and in vitro and in vivo experiments, Kong et al. demonstrated that genetic depletion of MAPK1 (which encodes ERK2), JUNB or FOSL (which encodes JUNB's binding partner protein, FRA1) blocked the death of drug-addicted cells.
The authors uncovered an exquisite specificity of action of the proteins involved. For example, depletion of ERK2 prevented cell death associated with drug addiction, but depletion of ERK1 had no effect on this process. This is consistent with the observation that when the drug was withdrawn from drug-addicted cells, ERK2 but not ERK1 was hyperactivated, even though both act in the same signalling pathway.
The drug-addiction pathway was the same regardless of how drug resistance had developed in a particular cell, for example by increased activation of the ERK pathway, or by an increase in the number of copies of BRAF. So the authors' findings might have relevance for the treatment of many people who have drug-resistant melanoma.
To determine how drug-addicted cells die when the drug is withdrawn, the authors sequenced RNA in this type of dying cell. As the
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Tumours addicted to drugs are vulnerable
Cancer cells can develop an 'addiction' to the drugs they are treated with, so that they need the drugs to survive. Analysis of the underlying mechanism reveals a potential clinical strategy for harnessing this phenomenon. See Letter p.270
Duncan and colleagues' work concerns these sporadics. The largest is known as the monster; it contains about 8 × 10 53 elements 3 and all but 6 of the other sporadics. The remaining 6 are jokingly called the pariahs. It could have been that every sporadic is completely disconnected from all other areas of mathematics and science. But the monster is not irrelevant: its representations show up in modular functions This discovery was completely unexpected. Nowadays, mathematicians explain the existence of monstrous moonshine by proposing that there is a two-dimensional quantum field theory, related to string theory, whose symmetry is the monster. Modular functions arise naturally in string theory, partly because the strings trace out surfaces as they move. In 1998, the mathematician Richard Borcherds was awarded the Fields Medal, the highest honour in mathematics, for his contribution to this work 5 (the story is described in ref. 6 ). Other moonshines, relating other sporadic groups to functions closely related to modular functions, have been discovered over the years. For example, Mathieu moonshine 7 involves a sporadic group that is called, by some, the most remarkable group of all, because it features in many different contexts. These moonshines all seem related to string theory, but the specific connections remain mysterious. Crucially, none have involved the pariahs. Mathematicians therefore began to suspect that perhaps the pariahs really were outcasts -Lego blocks too strange to be relevant.
Building on their earlier work 8 , Duncan et al. discovered a connection between the representations of a pariah called the O'Nan group 9 and the theory of elliptic curvescomplex curves shaped like the surfaces of doughnuts. The O'Nan group has approximately 5 × 10 11 elements 9 , which is about average for a pariah. Its representations give modular forms (closely related to modular functions) that contain intricate information about elliptic curves.
Duncan and colleagues' moonshine has a rather different flavour from that of the earlier discoveries. In particular, it is more difficult to see a possible connection to string theory. Because of this, the role that the O'Nan group has in nature remains unclear. Moreover, the precise relationship of its representations to elliptic curves needs to be fleshed out. The authors' discovery also raises the question of whether moonshines exist for the other pariahs, but this will require further work.
It is always difficult to gauge the importance of a mathematical result without the hindsight that many years brings. 2 investigated how a type of human cancer called melanoma responds to drug treatment using cells grown in vitro. When the cells are treated with inhibitor molecules that target the proteins BRAF or MEK, most die, although some might be resistant to the treatment and survive. If the resistant cells are treated with the inhibitor for a prolonged period, a phenomenon known as drug addiction can occur, in which the cells become dependent on the drug and some cells might rely on it for survival. Kong and colleagues identified several proteins involved in the drug-addiction pathway, including the protein ERK2. The authors observed high levels of ERK2 activation when inhibitor treatment was withdrawn from drug-addicted cells, causing some cell death. Furthermore, cell death could be increased if treatment with the chemotherapeutic agent dacarbazine was started at the same time as inhibitor treatment ceased. Phenotypic switching underlies the plasticity of melanoma cells and their ability to adapt to their microenvironment. The cellular state of melanoma cells can be identified by monitoring the expression of the E-cadherin protein or other proteins that are characteristic of a change -known as the EMTthat occurs when epithelial cells transition to become mesenchymal cells 4 . Phenotypic switching results in a cellular state in which cells have an increased probability of becoming metastatic, and the EMT change is part of the process that enables cells to metastasize. The EMT is regulated 4 in melanoma by the transcription factor protein MITF, which is the master regulator of the melanocyte-cell lineage 5 from which melanoma arises. Low levels of MITF are associated with an invasive metastatic state, whereas high levels are associated with proliferation 4 . The authors found that, in drug-addicted cells containing high levels of MITF, the MITF levels collapse on drug removal and the cells adopt an invasive form. When the authors used genetic engineering to prevent a decrease in MITF levels when drug was removed, the cell death associated with drug withdrawal was reduced. However, the role of MITF in this cell-death process is unclear, given that low levels of MITF expression are not known to cause cell death 4 . Kong and colleagues' work has clinical relevance in that, when the drug treatment was stopped, they identified a window during which treatment of melanoma cells grown in vitro with the chemotherapeutic agent dacarbazine could boost cell death (Fig. 1) . The authors propose that stopping the use of BRAF and MEK inhibitors, and starting the use of dacarbazine, would be more effective than merely halting all drug treatments in what are called 'drug-holiday' approaches aimed at promoting cell death by harnessing drug addiction.
The timing of drug treatment would be crucial. MEK inhibitors, in particular, have extremely long half-lives (up to 10 days) and, given that low levels of inhibition of this pathway could prevent cell death caused by drug addiction, correctly timed drug administration would be essential to achieve optimal benefit. There is clinical evidence 6 that retreatment with the targeted therapy can be effective after a drug holiday that was implemented as a result of disease progression or toxicity. The phenotypic switch from proliferative to invasive states might reset the sensitivity of the cells to targeted therapies, although this needs to be investigated.
The authors also tested another type of cancer called non-small cell lung cancer. They found that drug withdrawal decreases cell growth and induces an EMT cellular transition in a drug-resistant sample of these cancer cells grown in vitro and treated with an inhibitor of the EGFR protein (mutations in this protein are often associated with lung cancer). Again, this drug-addiction phenomenon was prevented by depletion of ERK2 but not of ERK1. These data suggest that drug addiction is a general feature associated with treatment by drugs that target proteins, such as EGFR, in the MAPK pathway. It will be interesting to discover whether drug addiction extends to therapies that target other signalling pathways, and to identify the key pathway components responsible.
The exciting work reported by Kong et al. consists mainly of in vitro studies, so in vivo work will be needed to examine whether the tumour microenvironment affects drug addiction. Their study also raises many fascinating questions: for example,why does ERK2 but not ERK1 mediate drug addiction, even though both are key components of the MAPK pathway. A complex network of feedback mechanisms regulates this pathway, and the role of these regulatory mechanisms in drug addiction should be investigated. The key to translating the authors' findings into clinical use will be determining whether other drugs work better than dacarbazine if used together with drug withdrawal to target drug-addicted cells. It would also be useful to investigate the mechanisms that underlie this type of synergy in greater detail. The improvements in our understanding of drug addiction that come from this latest work clearly offer a promising start in exploring the therapeutic opportunities that might arise from this Achilles heel of cancer. ■
